"There has never been a greater need for clinical trials of new therapies in lymphoma. I am therefore delighted that ACT’s commitment to fund the TAP and IMPACT networks will increase trial capacity in the UK and at the same…

“ACT’s innovative structure and ability to accelerate the delivery of practice informing trials in conjunction with the UK haematology-oncology community will be of real benefit to blood cancer patients for whom new and more effective therapies are so urgently needed"…

"At a time of rapid therapeutic innovation in blood cancers, new trial delivery models such as ACT are urgently needed. I am impressed with ACT's delivery to work with world class laboratories to deliver a truly transformative clinical trials proposition…